Category: General News

Roberto Bernardi is a dynamic author specialising in articles about technology, construction, and property. Originally from Italy, Roberto blends his deep-rooted European perspective with a forward-thinking approach to deliver insightful and practical content.
  • Longevity Science Is No Longer for the Elite: The Mainstream Wellness Treatments Backed by New Research

    Longevity Science Is No Longer for the Elite: The Mainstream Wellness Treatments Backed by New Research

    For years, the science of living longer and healthier was the exclusive preserve of Californian tech billionaires with private physicians and seven-figure health budgets. Bryan Johnson making headlines by transfusing his son’s blood plasma. Peter Thiel reportedly banking on parabiosis. The whole enterprise had an air of the baroque, even the desperate. But something has shifted, and it has shifted quickly. The longevity treatments 2026 are increasingly grounded in rigorous clinical evidence, increasingly available through UK private clinics, and increasingly affordable for anyone who takes their health with reasonable seriousness. This is not wellness fluff. It is a genuine pharmaceutical and diagnostic revolution.

    A woman reviewing longevity treatments 2026 data with her physician in a London private clinic
    A woman reviewing longevity treatments 2026 data with her physician in a London private clinic

    What Are Senolytics and Why Should You Care?

    The most significant clinical development in ageing science over the past decade is the emergence of senolytics: compounds that selectively clear senescent cells from the body. Senescent cells are, in the bluntest terms, cells that have stopped dividing but refuse to die. They accumulate with age and secrete a cocktail of inflammatory proteins that damage surrounding tissue, driving conditions from arthritis to cardiovascular disease to cognitive decline.

    The leading senolytic combination studied in human trials is dasatinib and quercetin. Dasatinib is a leukaemia drug; quercetin is a plant flavonoid found in onions and capers. Together, they have shown promising results in trials at the Mayo Clinic and, more recently, at University College London, where researchers observed measurable reductions in senescent cell burden in older patients with idiopathic pulmonary fibrosis. The regime is typically administered in short, intermittent bursts rather than daily dosing, which reduces side-effect risk considerably.

    In the UK, quercetin supplements are freely available from brands such as Viridian and Solgar. Dasatinib, being a prescription drug regulated by the MHRA, requires clinical oversight. A growing number of London-based longevity clinics, including Harpal Clinic and the Hooke Longevity Clinic in Marylebone, now offer senolytic protocols under medical supervision, typically priced between £800 and £2,500 for an initial programme including bloodwork and follow-up. That is not trivial, but it is a far cry from the seven-figure territory of five years ago.

    Continuous Glucose Monitoring: The Most Democratised Longevity Tool of the Era

    Perhaps no single longevity technology has crossed from elite experimentation into mainstream use as decisively as continuous glucose monitoring, or CGM. Originally designed for diabetics, the small sensor worn on the upper arm now appears on the bodies of triathletes, hedge fund managers and, increasingly, people who simply want to understand how their diet affects their metabolic health in real time.

    The clinical rationale is compelling. Chronic glycaemic variability, even in people who test as non-diabetic on standard fasting glucose tests, is associated with accelerated biological ageing, cognitive impairment and elevated cardiovascular risk. A CGM device reveals exactly how your body responds to white rice versus brown, a croissant versus porridge, alcohol versus sleep deprivation. The feedback loop is immediate and, for most users, genuinely revelatory.

    In the UK, Abbott’s Libre Sense and the Dexterity platform have made CGM accessible without a prescription for non-diabetic users through services such as Zoe, the gut microbiome and metabolic health company co-founded by Professor Tim Spector of King’s College London. Zoe’s programme, which costs approximately £299 for the initial testing phase, combines CGM data with microbiome analysis and personalised dietary recommendations. The NHS uses CGM extensively for Type 1 diabetes management, and there is growing advocacy for wider metabolic screening, particularly following ONS data showing that an estimated 3.8 million people in England are living with pre-diabetes, many undiagnosed.

    Continuous glucose monitoring sensor worn on the arm, a key longevity treatment in 2026
    Continuous glucose monitoring sensor worn on the arm, a key longevity treatment in 2026

    NAD+ Precursors: The Supplement With the Most Clinical Weight

    Nicotinamide adenine dinucleotide, NAD+, is a coenzyme present in every cell in the body and central to energy metabolism and DNA repair. Its levels decline steeply with age. Supplementing with NAD+ precursors, principally nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), has become one of the most studied areas in longevity science, with human trials now published in peer-reviewed journals including Nature Ageing and Cell Metabolism.

    The results are not uniformly dramatic. Some studies show improved muscle function, cognitive clarity and reduced markers of inflammation in older adults. Others show more modest effects. What is clear is that NR and NMN are generally well tolerated and that their mechanism of action is biologically plausible in a way that many wellness supplements simply are not. Elysium Health’s Basis, containing NR and pterostilbene, has amassed more human trial data than almost any other longevity supplement on the market. In the UK, NMN supplements are available from Renue By Science and Double Wood Supplements, typically at £40 to £90 per month, putting them firmly within mainstream reach.

    Rapamycin: The Most Discussed Drug You Have Probably Never Heard Of

    Rapamycin is an immunosuppressant typically used to prevent organ transplant rejection. It is also the most consistently life-extending compound ever tested in animal models, including mice, where it extended median lifespan by up to 25 per cent even when administered late in life. It works by inhibiting mTOR, a signalling pathway that governs cell growth and metabolism, effectively nudging cells into a more cautious, repair-oriented mode.

    Human data is still limited but accumulating. The PEARL trial and ongoing work at the Karolinska Institute in Stockholm are among the more rigorous human studies. In the UK, off-label rapamycin prescribing for longevity purposes remains uncommon but not unheard of, and is available through select private longevity physicians at a cost of roughly £150 to £400 per month, including medical monitoring. The risks, including immunosuppression and potential impact on wound healing, mean this is emphatically not a supplement to acquire without professional oversight.

    For a thorough review of the current evidence on pharmacological longevity interventions, the Lancet has published several accessible analyses in recent years, and remains the most authoritative English-language source for clinically grounded readers.

    The Cost of Longevity in 2026: A Realistic Assessment

    The honest picture of longevity treatments 2026 is one of tiered accessibility. At the most accessible end, CGM programmes and NMN supplementation are available to anyone spending £50 to £100 per month. Mid-tier interventions, supervised senolytic protocols, comprehensive bloodwork panels measuring biological age via DNA methylation testing (available from companies such as Chronomics, based in the UK), and structured rapamycin regimes, sit in the £500 to £3,000 annual range. At the apex, full-service longevity clinics offering everything from hyperbaric oxygen therapy to DEXA body composition scanning charge upwards of £5,000 per year for membership packages.

    What has changed is not that the top tier has become cheaper, but that genuinely evidence-backed interventions now exist at every price point. The longevity treatments 2026 landscape no longer requires you to be Peter Thiel. It does require you to be informed, to engage with real clinical evidence rather than marketing, and to work with qualified medical professionals when prescription-grade interventions are involved. The science has never been more serious. That, at least, is worth something.

    Frequently Asked Questions

    What are the most evidence-backed longevity treatments available in the UK in 2026?

    The treatments with the strongest clinical evidence include continuous glucose monitoring for metabolic health, NAD+ precursor supplements such as NMN and NR, and senolytic protocols combining quercetin with dasatinib. Rapamycin is also gaining attention but requires careful medical supervision due to its immunosuppressant properties.

    How much do longevity treatments cost in the UK?

    Costs vary considerably. CGM programmes such as Zoe start at around £299 for an initial phase, NMN supplements cost roughly £40 to £90 per month, and supervised senolytic protocols at private UK clinics typically range from £800 to £2,500. Full-service longevity clinic memberships can exceed £5,000 per year.

    Are senolytics safe to take without medical supervision?

    Quercetin, a key component of the leading senolytic combination, is available over the counter and is generally considered safe. However, dasatinib is a prescription-only drug regulated by the MHRA and should only be taken under qualified medical supervision, as it carries meaningful side-effect risks.

    What is continuous glucose monitoring and do I need a prescription to use it?

    Continuous glucose monitoring involves wearing a small sensor, usually on the upper arm, that tracks blood sugar levels in real time throughout the day. In the UK, non-diabetic users can access CGM through services such as Zoe without a prescription, though NHS-funded CGM remains primarily reserved for patients with Type 1 diabetes.

    Does the NHS offer any longevity-focused treatments or interventions?

    The NHS does not currently offer longevity treatments as a distinct category. However, it does provide CGM for diabetes management, statins for cardiovascular risk reduction, and screening programmes for certain cancers and conditions associated with ageing. Most of the newer longevity interventions discussed in this article are available only through private clinics.

  • The Slow Travel Revolution: Why Discerning Travellers Are Abandoning Packed Itineraries for Depth Over Distance

    The Slow Travel Revolution: Why Discerning Travellers Are Abandoning Packed Itineraries for Depth Over Distance

    There is a particular kind of exhaustion that only seasoned travellers recognise. The one that arrives not after a long journey, but after a meticulously scheduled one. Three cities in five days. A museum before breakfast, a flight before dinner. The photographs are extraordinary; the memories, oddly thin. Slow travel luxury 2026 has emerged as a direct and rather elegant rebuke to all of that.

    This is not a fringe movement. Among Britain’s more thoughtful, culturally literate travellers, the shift is palpable and, by most accounts, permanent. The question is no longer how many places you can fit into a fortnight, but how deeply you can inhabit one. Depth over distance, as the phrase goes, has become the defining principle of a new kind of luxury.

    A traveller contemplating the Alentejo landscape, embodying the slow travel luxury 2026 philosophy
    A traveller contemplating the Alentejo landscape, embodying the slow travel luxury 2026 philosophy

    What Is the Slow Travel Philosophy, and Why Is It Resonating Now?

    Slow travel, at its core, borrows from the broader slow movement that emerged from Carlo Petrini’s Slow Food manifesto in late-1980s Italy. Applied to travel, it advocates staying longer in fewer places, engaging with local rhythms rather than tourist schedules, and measuring the success of a trip by what you understand at the end of it rather than what you have ticked off. Whilst the concept has circulated in travel writing for over a decade, something shifted meaningfully in 2025 and 2026 to push it from pleasant idea to genuine cultural force.

    Part of the answer is post-pandemic recalibration. British travellers who spent enforced periods at home rediscovered the pleasure of noticing things slowly, paying attention to what is immediately around them. Part of it is environmental consciousness; staying in one place for two weeks produces a fraction of the carbon footprint that a multi-destination tour generates. And part of it is, frankly, the luxury market doing what it always eventually does: following genuine desire rather than manufactured aspiration. High-net-worth travellers, the kind who once collected Michelin-starred restaurants across four countries in a single trip, are increasingly choosing a single villa in the Alentejo for ten nights, with a private guide and a reading list curated by a local academic.

    The Destinations Leading the Slow Travel Movement in 2026

    Not every place lends itself to the slow travel ideal. The best destinations share certain qualities: genuine local culture that rewards attention, landscapes that change with the light, food that is tied to place rather than trend, and enough quiet that you can hear yourself think.

    Portugal’s Alentejo region remains, by most measures, the spiritual home of slow travel luxury in 2026. Its cork forests, medieval hilltop towns and sparse, amber-lit plains feel designed for contemplation. Properties such as Herdade do Esporão have developed extended-stay programmes centred on viticulture, agricultural heritage and serious gastronomy. You arrive expecting a holiday and leave with something closer to an education.

    Japan’s Tohoku region, long overshadowed by Kyoto and Tokyo on the standard itinerary, has attracted substantial attention from discerning travellers seeking the country’s quieter self. Ryokan stays of a week or longer, centred on particular craft traditions such as Aizu lacquerware or Tsugaru shamisen music, have become genuinely sought-after experiences. The point is not observation but participation.

    Handcrafted ceramics and local produce reflecting the slow travel luxury 2026 attention to detail
    Handcrafted ceramics and local produce reflecting the slow travel luxury 2026 attention to detail

    Closer to home, Scotland’s far north has quietly become a destination of remarkable depth for slow travellers. The Orkney archipelago, in particular, offers something almost nowhere else can: a landscape that contains 5,000 years of human history, severe and luminous weather, and a local community of artists, farmers and archaeologists whose work is inseparable from the terrain. Several independent properties now offer week-long residencies built around the islands’ creative and academic communities. The scenery is, of course, spectacular. But scenery alone does not sustain a slow traveller; context does.

    Why Slow Travel and Luxury Are, in Fact, Natural Partners

    There is a common misconception that slow travel is austerity travel, that it means budget accommodation and a deliberate rejection of comfort. The opposite tends to be true at the upper end of the market. True slow travel luxury in 2026 is expensive precisely because it requires extraordinary quality at every point of sustained contact. One spectacular dinner is a treat; ten consecutive brilliant meals require a chef, a network of local producers and genuine culinary intelligence. One beautiful bedroom is easy to find; a space you can genuinely live in for a fortnight demands curation of an entirely different order.

    The most sophisticated slow travel operators understand this. Scott Dunn, the British luxury travel specialist, has reported significant growth in extended single-destination bookings over the past eighteen months, with clients increasingly requesting programmes that include private tutors, local mentors and curated cultural immersions rather than conventional excursions. The measure of success has shifted from novelty to understanding.

    This also represents a meaningful redefinition of exclusivity. In a world where most wealthy travellers have been everywhere, having been nowhere thoroughly is, perversely, the more distinguished position. To have spent three weeks in one Umbrian valley, to know the name of the farmer who produces your olive oil and the history of the church you walked past each morning, is a form of knowledge that no amount of itinerary-hopping can replicate.

    The Environmental Case, Which Is Impossible to Ignore

    Slow travel is not an environmental panacea, and it would be intellectually dishonest to pretend otherwise. Flying to Portugal and staying for three weeks still involves a flight to Portugal. But the arithmetic is notably better than flying to five destinations across a fortnight, and the emerging class of slow travellers is increasingly supplementing or replacing flights with long-distance rail journeys. The BBC’s science and environment coverage has consistently noted that aviation accounts for roughly 2.5 per cent of global CO2 emissions but a far higher share of effective climate warming when contrasted effects are included. Reducing flight frequency matters, even when total travel remains high.

    The overland renaissance is a significant subplot of the slow travel story. The Caledonian Sleeper from London to Inverness, the Venice Simplon-Orient Express, and a growing number of premium rail routes across Europe have attracted travellers who once would have flown without a second thought. The journey, in the slow travel model, is not an inconvenience to be minimised but a first act of the experience itself.

    How to Actually Do Slow Travel Well

    The practical barriers are real. Most Britons receive between 25 and 28 days of annual leave; a fortnight in one place feels extravagant to many. But slow travel need not mean extended sabbaticals. A long weekend in one Yorkshire village, properly engaged with, produces more lasting memory than four European capitals in a week. The philosophy scales.

    For those planning a genuine immersive trip, the principles are straightforward. Arrive without a checklist. Identify two or three things you genuinely want to understand, whether that is the local textile tradition, a regional cooking technique, or the history of a particular landscape, and build your time around those. Stay somewhere that feels like habitation rather than accommodation. Eat with the rhythm of local life. Walk more than you think necessary. Resist the hotel’s activity programme unless it genuinely interests you.

    The slow travel movement, at its best, is simply an argument for taking seriously the places we choose to visit. It asks travellers to bring their full attention rather than their best luggage. In a world that accelerates almost everything by default, that particular kind of deliberateness feels, unexpectedly, like the most radical luxury of all.

    Frequently Asked Questions

    What does slow travel actually mean in practice?

    Slow travel means staying in fewer destinations for longer periods, prioritising genuine engagement with local culture, food and landscape over ticking off attractions. Rather than visiting five countries in a fortnight, a slow traveller might spend ten days in a single region, building real knowledge of the place rather than a curated highlight reel.

    Is slow travel luxury more expensive than conventional luxury holidays?

    Extended stays of genuine quality tend to cost more in absolute terms, simply because high standards must be maintained over a longer period. However, per-day costs can be lower, and many travellers find the value proposition far superior, as the depth of experience is incomparably richer than a succession of brief, expensive stops.

    Which are the best slow travel destinations for British travellers in 2026?

    Portugal’s Alentejo, Japan’s Tohoku region and Scotland’s Orkney archipelago are among the most compelling options for culturally serious slow travellers this year. Each rewards extended attention with layers of history, food culture and landscape that a short visit cannot hope to reach.

    Is slow travel actually better for the environment?

    It is generally more environmentally efficient than multi-destination travel, as it reduces the total number of flights taken. Combining slow travel with overland rail options, such as the Caledonian Sleeper or European train routes, reduces the carbon impact further, though a transatlantic flight remains significant regardless of how long you stay.

    Can slow travel work with a standard British annual leave allowance?

    Absolutely. The principles of slow travel apply at any scale; a long weekend spent properly exploring one part of the English countryside is slow travel in spirit. For those planning longer trips, combining annual leave with bank holidays strategically can create ten to twelve day windows that work well for genuinely immersive experiences.

  • Quantum Computing Just Became Real: What Every Business Needs to Know in 2026

    Quantum Computing Just Became Real: What Every Business Needs to Know in 2026

    For years, quantum computing occupied the same intellectual territory as fusion energy and human teleportation: endlessly promising, perpetually distant, and deeply convenient to ignore. That era is over. The quantum computing business impact in 2026 is no longer a matter of projection — it is a matter of preparation, and a significant number of British and European enterprises are already behind.

    What changed? In short: hardware stabilised, error correction made meaningful progress, and the major commercial players stopped waiting for perfection before deploying. IBM, Google, and a cohort of well-funded European challengers including Oxford-based Quantum Motion have moved from demonstration to early commercial access. The question is no longer whether quantum advantage is real. It is whether your sector is about to feel it first.

    Quantum computing business impact 2026 — cryogenic quantum processor in a British research facility
    Quantum computing business impact 2026 — cryogenic quantum processor in a British research facility

    What Does “Quantum Advantage” Actually Mean in Practice?

    The term gets thrown around with remarkable looseness. Quantum advantage, in its proper sense, describes the point at which a quantum computer solves a specific, commercially relevant problem faster or more accurately than any classical computer could, at a cost that makes deployment worthwhile. Notice the specificity. Quantum machines are not general-purpose replacements for the servers humming in data centres across the country. They are extraordinary at certain categories of problem: optimisation, simulation, and factorisation. Everything else, for now, remains firmly in classical territory.

    That distinction matters enormously when you are trying to assess risk or opportunity for your organisation. The businesses that will extract early value are those operating in domains where those three problem types are central. The businesses that should be most alarmed are those whose security infrastructure depends on the difficulty of factorisation. Which brings us directly to cybersecurity.

    The Cybersecurity Time Bomb: Harvest Now, Decrypt Later

    Britain’s National Cyber Security Centre (NCSC) has been direct about the threat. Adversaries are already harvesting encrypted data today, with the explicit intention of decrypting it once sufficiently powerful quantum machines become accessible. Government communications, financial records, medical histories, intellectual property: all of it potentially exposed to a retrospective breach that hasn’t technically happened yet but functionally already has.

    The NCSC’s guidance on post-quantum cryptography migration is not aspirational reading material for the future. It is an active operational priority. Organisations subject to UK regulatory frameworks, whether through the FCA, ICO, or sector-specific requirements, should treat their cryptographic estate as a live vulnerability. The migration to quantum-resistant algorithms is neither cheap nor swift; starting in 2026 is late, not early. You can read the NCSC’s post-quantum cryptography guidance directly at ncsc.gov.uk.

    Finance: Portfolio Optimisation and Risk Modelling at Unprecedented Scale

    The City has been watching quantum computing closely since at least 2019, and with good reason. Financial modelling is, at its core, an optimisation problem of extraordinary complexity. Pricing derivatives, stress-testing portfolios across thousands of correlated variables, detecting fraud patterns in real time — these tasks currently consume enormous classical computing resources and still return approximations rather than optima.

    Early quantum advantage in finance does not mean quantum computers replacing Bloomberg terminals next quarter. It means that within a narrow but high-value band of calculations, particularly Monte Carlo simulations and portfolio rebalancing at scale, hybrid quantum-classical systems are already demonstrating measurable improvements in speed and accuracy. HSBC and Barclays have both disclosed research partnerships in this space. For smaller asset managers and fintechs, the practical implication is that competitive edge will accrue to whoever integrates quantum-enhanced analytics first, even through cloud-based access rather than on-premises hardware.

    Quantum computing business impact on financial modelling and portfolio optimisation in 2026
    Quantum computing business impact on financial modelling and portfolio optimisation in 2026

    Pharmaceuticals: The Industry With the Most to Gain

    Arguably no sector stands to benefit more profoundly from genuine quantum computing business impact in 2026 and beyond than pharmaceuticals. Drug discovery is, fundamentally, a molecular simulation problem. Classical computers can model small molecules with reasonable accuracy, but the moment you move to the complex protein interactions relevant to most serious disease targets, the computational cost becomes prohibitive. Quantum computers simulate quantum systems natively — which is precisely what molecular chemistry is.

    AstraZeneca has publicly discussed quantum computing partnerships, and the wider UK life sciences sector, which contributes over £94 billion annually to the economy according to the Office for National Statistics, has strong strategic reasons to move quickly. A meaningful reduction in the time and cost of identifying viable drug candidates would be transformative. Early estimates suggest quantum-assisted drug discovery could compress certain phases of the development pipeline by years, not months. At a time when NHS procurement pressures and global health challenges demand faster therapeutic pipelines, the stakes are substantial.

    Logistics: The Optimisation Problem That Never Ends

    Supply chain optimisation is a domain where quantum advantage is already beginning to manifest in proof-of-concept work. Route planning, warehouse allocation, demand forecasting across complex multi-supplier networks: these are all variants of what mathematicians call the travelling salesman problem, notorious for its exponential classical complexity.

    For major British retailers and logistics operators — think the scale of Royal Mail, Tesco’s distribution network, or the Port of Felixstowe’s throughput management — even marginal improvements in routing efficiency translate into millions of pounds annually. Quantum optimisation is unlikely to replace classical logistics software wholesale, but as a supplementary layer applied to the hardest optimisation decisions, the value proposition is increasingly credible. Several UK logistics firms are already engaged in pilot programmes through IBM’s Quantum Network and similar platforms.

    What Should British Business Leaders Actually Do Right Now?

    The honest answer is: it depends entirely on your sector, your data sensitivity, and your competitive position. For most organisations, a two-track approach makes sense. The first track is defensive: audit your cryptographic infrastructure, begin understanding post-quantum migration requirements, and engage your IT security leadership on a realistic timeline for compliance. The second track is exploratory: identify the specific optimisation or simulation problems in your operations where quantum advantage might eventually apply, and begin building the internal literacy to evaluate vendor claims intelligently.

    Vendor claims, incidentally, deserve healthy scepticism. The gap between a press release announcing a quantum breakthrough and a deployable commercial solution remains wide in most cases. The organisations that will navigate this well are those that neither dismiss quantum as distant science fiction nor rush to expensive commitments based on hype. Informed, deliberate engagement is the appropriate posture.

    Britain’s Quantum Ambitions and the Stakes for UK Plc

    The UK government committed £2.5 billion to its National Quantum Strategy in 2023, with significant tranches being deployed through 2026 via Innovate UK and the Engineering and Physical Sciences Research Council. Britain has genuine world-class capability in this field: the universities of Oxford, Cambridge, and Bristol rank amongst the leading quantum research institutions globally.

    Whether that academic excellence converts into commercial leadership is the defining question. The quantum computing business impact in 2026 is real, targeted, and accelerating. The industries most exposed to disruption and most positioned for advantage have been identified. The window for deliberate preparation, rather than reactive scrambling, is still open. Just not indefinitely.

    Frequently Asked Questions

    What is quantum computing business impact in 2026 actually referring to?

    It refers to the practical, commercial effects of early quantum advantage becoming accessible to businesses across sectors including finance, pharmaceuticals, logistics, and cybersecurity. In 2026, this means hybrid quantum-classical systems delivering measurable improvements in specific high-complexity tasks, rather than wholesale replacement of existing computing infrastructure.

    Should UK businesses be worried about quantum computing breaking their encryption?

    Yes, with appropriate urgency rather than panic. The NCSC has issued guidance on post-quantum cryptography migration, acknowledging that adversaries may already be harvesting encrypted data for future decryption. Any UK organisation holding sensitive data under FCA, ICO, or similar regulatory frameworks should review their cryptographic estate now.

    How does quantum computing help the pharmaceutical industry?

    Quantum computers can simulate molecular interactions natively, which is precisely what drug discovery requires. This could dramatically reduce the time needed to identify viable drug candidates and accelerate clinical pipeline development, with major implications for UK life sciences, which contributes over £94 billion annually to the economy.

    Do businesses need to buy quantum hardware to benefit?

    Not at all. Cloud-based quantum access through platforms like IBM Quantum Network, Microsoft Azure Quantum, and others allows organisations to run quantum algorithms without any on-premises hardware investment. This significantly lowers the barrier to early experimentation and pilot deployment.

    How does quantum computing differ from regular high-performance computing?

    Classical high-performance computing scales up conventional binary processing, using more and faster traditional processors. Quantum computing uses qubits that exploit superposition and entanglement to process certain problem types, particularly optimisation, simulation, and factorisation, in fundamentally different and far more efficient ways than any classical approach can.

The Latest